Total Payments
$19,822
2024 Payments
$1,722
Companies
34
Transactions
160
Medicare Patients
3,950
Medicare Billing
$268,315
Payment Breakdown by Category
Other$15,468 (78.0%)
Food & Beverage$4,309 (21.7%)
Education$45.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,468 | 3 | 78.0% |
| Food and Beverage | $4,309 | 155 | 21.7% |
| Education | $45.00 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lumenis, Inc | $15,468 | 3 | $0 (2019) |
| Lumenis BE inc | $1,320 | 1 | $0 (2024) |
| ABBVIE INC. | $1,235 | 56 | $0 (2024) |
| Janssen Biotech, Inc. | $310.01 | 20 | $0 (2023) |
| GENZYME CORPORATION | $179.81 | 10 | $0 (2024) |
| Galderma Laboratories, L.P. | $174.05 | 10 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $124.99 | 1 | $0 (2017) |
| Mayne Pharma Inc. | $106.65 | 6 | $0 (2019) |
| Amgen Inc. | $98.91 | 4 | $0 (2023) |
| Sun Pharmaceutical Industries Inc. | $77.66 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,722 | 8 | Lumenis BE inc ($1,320) |
| 2023 | $176.41 | 8 | ABBVIE INC. ($67.08) |
| 2022 | $185.36 | 9 | ABBVIE INC. ($107.28) |
| 2021 | $46.89 | 3 | Janssen Biotech, Inc. ($19.20) |
| 2020 | $144.85 | 8 | UCB, Inc. ($23.35) |
| 2019 | $7,114 | 35 | Lumenis, Inc ($6,468) |
| 2018 | $6,632 | 44 | Lumenis, Inc ($6,000) |
| 2017 | $3,800 | 45 | Lumenis, Inc ($3,000) |
All Payment Transactions
160 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Lumenis BE inc | M22 (Device) | Food and Beverage | Cash or cash equivalent | $1,319.98 | General |
| Category: Dermathology | ||||||
| 09/09/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 09/03/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: DERMATOLOGY | ||||||
| 08/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Immunology | ||||||
| 06/05/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Dermatology | ||||||
| 05/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Immunology | ||||||
| 04/09/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $142.95 | General |
| Category: FACIAL AESTHETICS | ||||||
| 02/20/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $150.27 | General |
| 10/17/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $31.93 | General |
| Category: Inflammation | ||||||
| 09/08/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.70 | General |
| Category: IMMUNOLOGY | ||||||
| 08/17/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Immunology | ||||||
| 07/27/2023 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $20.66 | General |
| 07/19/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: IMMUNOLOGY | ||||||
| 04/20/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: Immunology | ||||||
| 03/23/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Immunology | ||||||
| 01/10/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Inflammation | ||||||
| 12/13/2022 | ABBVIE INC. | RINVOQ (Biological), RINVOQ | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Inflammation | ||||||
| 07/29/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/13/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Immunology | ||||||
| 06/28/2022 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Inflammation & Immunology | ||||||
| 06/07/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Immunology | ||||||
| 05/10/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: IMMUNOLOGY | ||||||
| 05/03/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: IMMUNOLOGY | ||||||
| 01/26/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 832 | 1,513 | $128,950 | $59,093 |
| 2022 | 9 | 929 | 1,727 | $136,195 | $62,872 |
| 2021 | 7 | 921 | 1,705 | $136,465 | $68,205 |
| 2020 | 12 | 1,268 | 2,149 | $171,215 | $78,145 |
Total Patients
3,950
Total Services
7,094
Medicare Billing
$268,315
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 244 | 336 | $52,080 | $27,601 | 53.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 191 | 286 | $27,170 | $9,969 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 137 | $15,070 | $7,835 | 52.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 58 | 69 | $9,450 | $5,180 | 54.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 52 | 62 | $8,990 | $3,618 | 40.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 136 | 580 | $11,600 | $2,487 | 21.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $2,380 | $1,285 | 54.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 26 | $2,210 | $1,119 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 200 | 254 | $38,100 | $20,722 | 54.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 195 | 271 | $27,100 | $15,451 | 57.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 202 | 308 | $29,260 | $10,811 | 36.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 76 | 85 | $11,050 | $6,192 | 56.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 67 | 76 | $11,020 | $4,108 | 37.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 149 | 690 | $13,800 | $2,983 | 21.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 11 | 12 | $2,460 | $1,253 | 50.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $1,960 | $701.43 | 35.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 17 | $1,445 | $650.92 | 45.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 194 | 228 | $33,780 | $20,183 | 59.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 194 | 279 | $27,450 | $17,004 | 61.9% |
| 17000 | Destruction of skin growth | Office | 2021 | 226 | 323 | $30,685 | $11,920 | 38.8% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 73 | 85 | $11,050 | $6,328 | 57.3% |
| 15789 | Chemical peel of skin of face, deep layer | Office | 2021 | 11 | 14 | $9,730 | $5,659 | 58.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 59 | 66 | $9,570 | $3,907 | 40.8% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 164 | 710 | $14,200 | $3,204 | 22.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 266 | 312 | $37,440 | $22,399 | 59.8% |
About Dr. Chad Hivnor, MD
Dr. Chad Hivnor, MD is a Dermatology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1477544476.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chad Hivnor, MD has received a total of $19,822 in payments from pharmaceutical and medical device companies, with $1,722 received in 2024. These payments were reported across 160 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($15,468).
As a Medicare-enrolled provider, Hivnor has provided services to 3,950 Medicare beneficiaries, totaling 7,094 services with total Medicare billing of $268,315. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location San Antonio, TX
- Active Since 10/31/2005
- Last Updated 06/26/2014
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1477544476
Products in Payments
- M22 (Device) $1,320
- Humira (Biological) $580.31
- BOTOX (Biological) $142.95
- EPIDUO FORTE (Drug) $134.66
- DUPIXENT (Drug) $129.55
- Skyrizi (Biological) $126.66
- Otezla (Drug) $123.06
- DORYX (Drug) $106.65
- TREMFYA (Drug) $106.60
- STELARA (Biological) $96.70
- SKYRIZI (Biological) $93.14
- RINVOQ (Biological) $91.49
- ILUMYA (Biological) $77.66
- Cimzia (Drug) $75.09
- DUPIXENT (Biological) $66.67
- REMICADE (Biological) $58.84
- TALTZ (Drug) $57.39
- DUPIXENT DUPILUMAB INJECTION (Biological) $52.17
- Tremfya (Drug) $47.87
- ENSTILAR (Drug) $35.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in San Antonio
Dr. William Cragun, M.d, M.D
Dermatology — Payments: $1.9M
Dermatology $1.9M
Emily Becker, M.d, M.D
Dermatology — Payments: $937,773
Dermatology $937,773
Dr. Mark Lee, M.d, M.D
Dermatology — Payments: $589,973
Dermatology $589,973
Dr. Lindsey Finklea, M.d, M.D
Dermatology — Payments: $265,879
Dermatology $265,879
Steven Davis, Md, MD
Dermatology — Payments: $114,713
Dermatology $114,713
Stephen Miller, M.d. P.a, M.D. P.A
Dermatology — Payments: $89,896
Dermatology $89,896